BioSpace News Archive

Drug Development

Large Study Suggests Convalescent Antibodies May Help Treat COVID-19

The results from a three-month study in more than 35,000 patients were published yesterday on a preprint server, which means they have not yet been peer-reviewed.

August 14, 2020
·
3 min read
·
Mark Terry
Policy

U.K. Government Secures 60 Million Doses of Novavax’s COVID-19 Vaccine Candidate

Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the vaccine should it be approved, as well as a late-stage efficacy study in that country.

August 14, 2020
·
2 min read
·
Alex Keown
Policy

FDA Action Alert: Bristol Myers Squibb/Juno, Seattle Genetics, BioMarin and Tricida

With a busy August on the U.S. Food and Drug Administration’s schedule, this week is no exception. Here’s a look at some of what’s on the agency’s calendar.

August 14, 2020
·
4 min read
·
Mark Terry
Drug Development

Sinopharm Publishes Positive Data from Phase I/II COVID-19 Vaccine Study

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

August 14, 2020
·
2 min read
·
Alex Keown
Drug Development

New RDIF Website Details Russia’s COVID-19 Vaccine as Global Phase III Trials Begin

Phase III clinical trials for Russia’s Sputnik V vaccine for COVID-19 began Wednesday, one day after the Russia Direct Investment Fund (RDIF) launched a new website to share the details of the vaccine with the public and scientists around the world.

August 14, 2020
·
4 min read
·
Gail Dutton
Deals

Germany’s CureVac Scores $213 Million in IPO

Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.

August 14, 2020
·
2 min read
·
Alex Keown
Drug Development

Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.

August 14, 2020
·
14 min read
·
Chelsea Weidman Burke
BioCapital

Clinical Catch-Up: August 10-14

It was a very busy week for clinical trial updates. Here’s a look.

August 14, 2020
·
7 min read
·
Mark Terry
Business

TFF Pharma and UNION Therapeutics Ink Deal to Develop Niclosamide for COVID-19

Niclosamide is an oral anthelminthic drug. It was first approved by the U.S. Food and Drug Administration (FDA) in 1982 and is included in the World Health Organization (WHO)’s list of essential medicines.

August 14, 2020
·
3 min read
·
Mark Terry
DNA/Gene Microarray Market - Growing Number of Genetic Disorders Highlights Need for DNA/Gene Microarray Services

In recent years, there is considerable increase in the number of people living with genetic disorders. This fact has compelled researchers from all across the world to growing their efforts on study of genetics.

August 14, 2020
·
3 min read